1. Home
  2. VRTX

VRTX

Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated

Technology

EDP Services

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Founded: 1989 Country:
United States
United States
Employees: 5400 City: BOSTON
Market Cap: 103.4B IPO Year: 1991
Target Price: $421.86 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 26
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 13.89 EPS Growth: 8.35
52 Week Low/High: $316.43 - $448.40 Next Earning Date: 05-06-2024
Revenue: $9,869,200,000 Revenue Growth: 10.51%
Revenue Growth (this year): 10.73% Revenue Growth (next year): 9.36%

Share on Social Networks: